Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD

Blood (2017) 130 (Supplement 1): 4996.

https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996

Published: 2017

Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2920.

https://doi.org/10.1182/blood.V126.23.2920.2920

Published: 2015

Journal Articles

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven E. Coutre, Don M. Benson, Ian W. Flinn, Nina D. Wagner-Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste Bello, Heather K. Webb, Dave M. Johnson, Sissy Peterman, Daniel Li, Thomas M. Jahn, Brian J. Lannutti, Roger G. Ulrich, Albert S. Yu, Langdon L. Miller, Richard R. Furman

Blood (2014) 123 (22): 3390–3397.

https://doi.org/10.1182/blood-2013-11-535047

Published: 2014

Includes: Supplemental data

Journal Articles

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard, Richard R. Furman, Jennifer R. Brown, John C. Byrd, Nina D. Wagner-Johnston, Steve E. Coutre, Don M. Benson, Sissy Peterman, Yoonjin Cho, Heather K. Webb, David M. Johnson, Albert S. Yu, Roger G. Ulrich, Wayne R. Godfrey, Langdon L. Miller, Stephen E. Spurgeon

Blood (2014) 123 (22): 3406–3413.

https://doi.org/10.1182/blood-2013-11-538546

Published: 2014

Journal Articles

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

Sarah A Meadows, Adam Kashishian, David Johnson, Roger G Ulrich, Langdon L Miller, Brian J. Lannutti, PhD

Blood (2011) 118 (21): 3730.

https://doi.org/10.1182/blood.V118.21.3730.3730

Published: 2011

Journal Articles

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

Blood (2011) 117 (2): 591–594.

https://doi.org/10.1182/blood-2010-03-275305

Published: 2011

Includes: Supplemental data

Journal Articles

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Steven E. Coutre, MD, Don M Benson, Jr., MD, Nina D. Wagner-Johnston, Ian W. Flinn, MD, PhD, Brad S. Kahl, MD, Stephen E. Spurgeon, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Heather K Webb, Ph.D., Roger G Ulrich, Ph.D., Sissy Peterman, Leanne M. Holes, Albert S Yu, MD

Blood (2010) 116 (21): 55.

https://doi.org/10.1182/blood.V116.21.55.55

Published: 2010

Journal Articles

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Heather K Webb, Ph.D., Hao Chen, Ph.D., Albert S Yu, M.D., Sissy Peterman, Leanne Holes, Brian Lannutti, PhD, Langdon L. Miller, MD, Roger G Ulrich, Ph.D.

Blood (2010) 116 (21): 1774.

https://doi.org/10.1182/blood.V116.21.1774.1774

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Sarah E. May, Adam Kashishian, Thomas S. Lin, MD, PhD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Roger G. Ulrich, PhD, Hao Chen, PhD, Albert S. Yu, MD, PhD, Kamal D. Puri, PhD, BSc, MSc, Brian J. Lannutti, PhD, Neill A. Giese, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2008) 112 (11): 3165.

https://doi.org/10.1182/blood.V112.11.3165.3165

Published: 2008

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese

Blood (2008) 112 (11): 16.

https://doi.org/10.1182/blood.V112.11.16.16

Published: 2008

NARROW

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only